Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4Thoracic 1Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 96Head and Neck Neoplasms 73Carcinoma, Non-Small-Cell Lung 34Thyroid Neoplasms 29Melanoma 26Ovarian Neoplasms 25Mouth Neoplasms 23Colorectal Neoplasms 20Oropharyngeal Neoplasms 19Breast Neoplasms 18Uterine Cervical Neoplasms 16Carcinoma, Squamous Cell 16Nasopharyngeal Carcinoma 15Lung Neoplasms 15Carcinoma, Renal Cell 15Neoplasm Metastasis 14Urinary Bladder Neoplasms 13Stomach Neoplasms 13Sarcoma 13Laryngeal Neoplasms 13Triple Negative Breast Neoplasms 12Prostatic Neoplasms 12Carcinoma 12Esophageal Neoplasms 11Endometrial Neoplasms 11Neoplasms 10Pancreatic Neoplasms 9Hypopharyngeal Neoplasms 9Salivary Gland Neoplasms 8Carcinoma, Transitional Cell 7

Interventions

ebselen 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Hearing Loss × Head & Neck × 30 days × Clear all
NCT04915183 2026-06-05

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
224 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

NCT07407582 2026-06-05

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

University of Arizona

Phase 1/2 Recruiting
25 enrolled
GenitourinaryHead & Neck

Head and Neck Neoplasms, Neoplasms, Testicular Neoplasms, Hearing Loss

NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Withdrawn
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

NCT07622407 2026-06-03

TIMELY REHAB

VA Office of Research and Development

Phase NA Not yet recruiting
74 enrolled
Head & Neck

Ototoxicity, Deglutition Disorders, Head and Neck Neoplasms, Hearing Loss, Sensorineural, Tinnitus, Hearing Loss, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡